TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01622673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 400 mg oral tablet taken with 240 mL water every 12 hours~Throughout the study, participants will continue to take raltegravir along with their other HIV medications. On the day of co-dosing and intensive pharmacokinetic (PK) sampling, raltegravir will be dosed in the morning in a fasted state in all periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 400 mg oral tablet taken with 240 mL water every 12 hours~Throughout the study, participants will continue to take raltegravir along with their other HIV medications. On the day of co-dosing and intensive pharmacokinetic (PK) sampling, raltegravir will be dosed in the morning in a fasted state in all periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 400 mg oral tablet taken with 240 mL water every 12 hours~Throughout the study, participants will continue to take raltegravir along with their other HIV medications. On the day of co-dosing and intensive pharmacokinetic (PK) sampling, raltegravir will be dosed in the morning in a fasted state in all periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 400 mg oral tablet taken with 240 mL water every 12 hours~Throughout the study, participants will continue to take raltegravir along with their other HIV medications. On the day of co-dosing and intensive pharmacokinetic (PK) sampling, raltegravir will be dosed in the morning in a fasted state in all periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 400 mg oral tablet taken with 240 mL water every 12 hours~Throughout the study, participants will continue to take raltegravir along with their other HIV medications. On the day of co-dosing and intensive pharmacokinetic (PK) sampling, raltegravir will be dosed in the morning in a fasted state in all periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TUMS® Ultra Strength
Description: 3 tablets TUMS® Ultra Strength (US) 1000 mg~Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods.
Study: NCT03793361

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets - Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression~Provided by BAYER
Study: NCT03000829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-intensivist consultation
Description: Standardized consultation to on-site cardiac arrest team by off-site intensivist via two-way audiovisual link using a mobile telemedicine cart

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Simulated observation by ICU physician
Description: Display of silent, pre-recorded, non-interactive videotape of an ICU physician. The on-site cardiac arrest team will be told that an intensive care physician is observing the mock code.
Study: NCT02682316

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dry gauze

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Prevena Incision Management System
Study: NCT04257812

Intervention type: DRUG
Intervention: Ceftolozane/tazobactam
Description: The dose will be 1g ceftolozane + 0,5 g tazobactam every 8 hours or 2 g ceftolozane + 1 g tazobactam, it´s recommended to use this last dose regimen in patients with pneumonia or septic shock of any focus.~The patients will be followed as it´s done habitually. There will be done infection focus cultures and others according to usual clinical practice. It´ll be determined the clinical response and mortality in the days 14 and 30 after the beginning of the medicine, respectively.~The Ceftolozane-Tazobactam levels determination will always be made in state of equilibrium (after the third dose). Four samples will be collected:~1. Just before the antibiotic infusion.~2. One hour after the antibiotic infusion.~3. Three hours after the antibiotic infusion.~4. Six hours after the antibiotic infusion.
Study: NCT04914728

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mini-invasive lumbar arthrodesis
Description: * The mini-invasive posterior approach is performed using a trans-muscular Wiltse approach. Pedicle screws, neurological decompression and intersomatic cage placement are performed.~* The mini-invasive anterior approach is performed via a left retroperitoneal pararectal approach. After complete discectomy, an intersomatic cage stabilised by a screwed plate will be placed.
Study: NCT01489969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neu-P11
Description: 1 tablet daily 1-2 before bed time for 28 days of double blind treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neu-P11
Description: 1 tablet daily 1-2 before bed time for 28 days of double blind treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neu-P11
Description: 1 tablet daily 1-2 before bed time for 28 days of double blind treatment
Study: NCT00267865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 6000 mg/m\^2 will be administered by intravenous infusion over 4 hours after confirming that the recipient patients urine pH is within the range greater than or equal to 7 to less than or equal to 8, and urine output is greater than or equal to 100 mL/hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 intravenous (IV) day 1 of each cycle prior to administration of high-dose methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin calcium doses will be administered orally or by short intravenous (IV) infusion over 15 minutes
Study: NCT01715818

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching aleglitazar placebo tablet orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: 150 mcg orally daily
Study: NCT02347566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity enhancing programme
Description: COPD patients performing pulmonary rehabilitation will wear the DirectLife activity monitor with set targets and feedback. They will have access to a web coaching programme. Their physical activity targets will be updated on a weekly basis in order to enhance their physical activity.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: COPD patients performing pulmonary rehabilitation will wear the DirectLife activity monitor without set targets and/or feedback. They will not have access to a web coaching programme.
Study: NCT00992810

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral-to-Medial Approach
Description: Approach of the needle to administer the brachial plexus nerve block will be done in a lateral-to-medial direction.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Media-to-Lateral Approach
Description: Approach of the needle to administer the brachial plexus nerve block will be done in a medial-to-lateral direction.
Study: NCT00691496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention to reduce sexual risk among African-American men who have sex with men
Description: 5 week intervention to increase skill level of participants with talking to their social networks and sexual partners about reducing high risk sexual behaviors while preparing a healthy meal
Study: NCT01904708

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute Moderate Intensity Exercise
Description: Moderate intensity exercise by walking on a treadmill at 75% of max heart rate.
Study: NCT03202004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2894512 1% cream
Description: 1 % (10 mg/g) GSK2894512 cream will be provided in tubes labeled in compliance with country requirements.
Study: NCT04445246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled ILOPROST
Description: Inhaled Iloprost 20 mcg every 8 hours for 5 days only delivered by nebulization.
Study: NCT01923935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BUSULFEX®
Description: BUSULFEX® 3.2 mg/kg/day iv once daily over 3 hours (day-6\~day-4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alkeran®
Description: Alkeran® 70 mg/m2/day iv once daily over 30 minutes (day-3\~day-2)
Study: NCT03686176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: A child life specialist will fit the patient with the goggles, select a game, and initiate play once the medical procedure begins.
Study: NCT01434355

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04321096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat Mesilate
Description: Serine protease inhibitor that blocks TMPRSS-2 mediated cell entry of SARS-CoV-2
Study: NCT03202004

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle cream will be provided in tubes labeled in compliance with country requirements.
Study: NCT00359684

Intervention type: DRUG
Intervention: Cysteamine
Description: Cystine-depleting agent
Study: NCT04001790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Search plus ASD Supports
Description: Nine month job training program embedded on Fort Eustis military base.
Study: NCT02461173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Merional
Description: On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IUI
Description: Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IUI
Description: Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovulation detection
Description: Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovulation detection
Description: Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Choriomon
Description: Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: shepherd catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: shepherd catheter
Study: NCT04338685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7119929
Description: RO7119929 will be administered orally as a capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7119929
Description: RO7119929 will be administered orally as a capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7119929
Description: RO7119929 will be administered orally as a capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7119929
Description: RO7119929 will be administered orally as a capsule
Study: NCT01622673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TUMS® Ultra Strength
Description: 3 tablets TUMS® Ultra Strength (US) 1000 mg~Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TUMS® Ultra Strength
Description: 3 tablets TUMS® Ultra Strength (US) 1000 mg~Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods.
Study: NCT04338685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7119929
Description: RO7119929 will be administered orally as a capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7119929
Description: RO7119929 will be administered orally as a capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7119929
Description: RO7119929 will be administered orally as a capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7119929
Description: RO7119929 will be administered orally as a capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered in case of severe steroid-refractory cytokine release syndrome.~Tocilizumab will be administered as concentrate for solution for IV infusion at a dose: for participants \> 30 kg: 8 mg/kg, for participants \< 30 kg: 12mg/kg IV
Study: NCT04566016

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional anesthesia
Description: Patients scheduled for lower limb arterial bypass surgery will be randomly allocated for treatment with spinal anesthesia associated with spontaneous ventilation (nasal cannula with supplemental oxygen - Group 1) or treatment with general anesthesia under controlled mechanical ventilation (tidal volume 6 to 8 ml / kg of the predicted body weight and PEEP of 5 cmH2O - Group 2).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional anesthesia
Description: Patients scheduled for lower limb arterial bypass surgery will be randomly allocated for treatment with spinal anesthesia associated with spontaneous ventilation (nasal cannula with supplemental oxygen - Group 1) or treatment with general anesthesia under controlled mechanical ventilation (tidal volume 6 to 8 ml / kg of the predicted body weight and PEEP of 5 cmH2O - Group 2).
Study: NCT01622673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TUMS® Ultra Strength
Description: 3 tablets TUMS® Ultra Strength (US) 1000 mg~Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods.
Study: NCT03427931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM)
Description: Study subjects will collect Continuous Glucose Monitor data for a minimum of 28 days but may continue for up to 3 months.
Study: NCT03378531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB1102
Description: modified human arginase I
Study: NCT04321096

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo
Study: NCT02451995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ripple Mapping guided AT ablation
Description: Diagnosing the mechanism and delivering ablation within the atria in patients with atrial tachycardia on the basis of Ripple Mapping

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Local activation Time Mapping AT Ablation
Description: Diagnosing the mechanism and delivering ablation within the atria in patients with atrial tachycardia on the basis of local activation time mapping
Study: NCT00779025

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PD-F-5254
Description: Female Personal Lubricant (MINE)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PD-F-5254
Description: Female Personal Lubricant (MINE)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10855-096
Description: Male Personal Lubricant (YOURS)
Study: NCT05971927

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation education
Description: Randomly assigned experimental group students performed eight different vaginal examination scenarios in the laboratory on the fetal monitoring and labor progress model set for cervical dilatation, cervical effacement, presenting fetal part, presence of amniotic membrane and fetal descent. The researchers repeated the vaginal examination scenario and informed the students about the evaluation results after each student had performed the vaginal examination scenario prepared by the researchers. This process continued until the experimental group students completed eight different vaginal examination scenarios.
Study: NCT03941717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Condition
Description: Each script for the mindfulness-based intervention was slightly modified to fit the context of a venipuncture, and begins with instructions to take deep breaths. Both scripts aim to cultivate present moment awareness of experiences, curiosity, nonjudgement, and acceptance of experiences as they unfold. In particular, the scripts ask that the participant visualize their worries and feelings as a cloud in the sky, and probes for curious thoughts about these experiences. The temporary nature of sensations is described, and the participant is asked to keep this openness and curiosity during the venipuncture.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Unfocused attention Condition
Description: Each script for the unfocused attention task instructs participants to allow their mind and thoughts to roam. The aim is to encourage the participant to continue thinking and mind wandering as they typically would.
Study: NCT02716623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CR diet
Description: Diet consists of meals lower in carbohydrates but does not restrict the number of calories that participants can consume.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will be asked to undergo specific exercise schedule. Exercise will be tracked using a fitness device.
Study: NCT04191317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education and gradual exposure
Description: Education covering the pathophysiology of apin and exercises based on the gradual exposure principle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates and postural education
Description: Postural education and pilates exercises
Study: NCT03031366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3d roadmap guidance
Description: TIPS was established using 3d roadmap

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional TIPS procedure
Description: conventional TIPS procedure using wedged hepatic venography
Study: NCT02246426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized plasticity-based adaptive cognitive training
Description: Computerized plasticity-based adaptive cognitive training for a total maximum of 40 treatment sessions, 3-5 times weekly, 40-60 minutes per session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available computerized training
Description: Commercially available computerized training for a total maximum of 40 treatment sessions, 3-5 times weekly, 40-60 minutes per session.
Study: NCT01771523

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thyroidectomy
Description: total thyroidectomy or lobectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thyroidectomy
Description: total thyroidectomy or lobectomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: use of drain
Description: drain will be used
Study: NCT04741919

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Yag Laser peripheral Iridotomy
Description: Laser peripheral iridotomy will be performed using neo-dynium:yttrium:aluminium-garnet laser after pretreatment with 2% pilocarpine and brimonidine 0.15%. Superior LPIs will be placed between the 11- and 1-o'clock positions such that they were covered completely by the upper eyelid; nasal/temporal LPIs will be placed between the 2- and 4-o'clock positions or the 8- and 10-o'clock positions such that they were completely clear of the lid margin. Preference will be given to iris crypts, avoiding iris vessels when possible. Laser peripheral iridotomies will be performed in both eyes during the same visit and will be confirmed to be patent after the procedure. Intraoperative data collected will include initial per-shot laser energy in milli joules, number of laser shots, and total laser energy in millijoules. All the patients will be treated with flurometholone 0.1% eye drops QID for 5 days after surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Yag Laser peripheral Iridotomy
Description: Laser peripheral iridotomy will be performed using neo-dynium:yttrium:aluminium-garnet laser after pretreatment with 2% pilocarpine and brimonidine 0.15%. Superior LPIs will be placed between the 11- and 1-o'clock positions such that they were covered completely by the upper eyelid; nasal/temporal LPIs will be placed between the 2- and 4-o'clock positions or the 8- and 10-o'clock positions such that they were completely clear of the lid margin. Preference will be given to iris crypts, avoiding iris vessels when possible. Laser peripheral iridotomies will be performed in both eyes during the same visit and will be confirmed to be patent after the procedure. Intraoperative data collected will include initial per-shot laser energy in milli joules, number of laser shots, and total laser energy in millijoules. All the patients will be treated with flurometholone 0.1% eye drops QID for 5 days after surgery.
Study: NCT00475709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trifecta Aortic Heart Valve
Description: Surgical replacement of the aortic valve with the Trifecta Aortic Heart Valve.